Evidence map›Paper›PMID 35613556›Full record

ArticleAmerican journal of nephrology2022

Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.

Shosha E I Dekker, Aswin Verhoeven, Daria Frey, Darius Soonawala, Dorien J M Peters, Oleg A Mayboroda, Johan W de Fijter, DIPAK Consortium

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Biomarkers of Kidney Disease Progression in ADPKD.Kidney international reports · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shosha E I DekkerDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands, s.e.i.dekker@lumc.nl.
Aswin VerhoevenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Daria FreyDepartment of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
Darius SoonawalaDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Dorien J M PetersDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Oleg A MayborodaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Johan W de FijterDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
DIPAK Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn autosomal dominant polycystic kidney disease (ADPKD) patients, predicting renal disease progression is important to make a prognosis and to support the clinical decision whether to initiate renoprotective therapy. Conventional markers all have their limitations. Metabolic profiling is a promising strategy for risk stratification. We determined the prognostic performance to identify patients with a fast progressive disease course and evaluated time-dependent changes in urinary metabolites.

methodsTargeted, quantitative metabolomics analysis (1H NMR-spectroscopy) was performed on spot urinary samples at two time points, baseline (n = 324, 61% female; mean age 45 years, SD 11; median eGFR 61 mL/min/1.73 m2, IQR 42-88; mean years of creatinine follow-up 3.7, SD 1.3) and a sample obtained after 3 years of follow-up (n = 112). Patients were stratified by their eGFR slope into fast and slow progressors based on an annualized change of > -3.0 or ≤ -3.0 mL/min/1.73 m2/year, respectively. Fifty-five urinary metabolites and ratios were quantified, and the significant ones were selected. Logistic regression was used to determine prognostic performance in identifying those with a fast progressive course using baseline urine samples. Repeated-measures ANOVA was used to analyze whether changes in urinary metabolites over a 3-year follow-up period differed between fast and slow progressors.

resultsIn a single urinary sample, the prognostic performance of urinary metabolites was comparable to that of a model including height-adjusted total kidney volume (htTKV, AUC = 0.67). Combined with htTKV, the predictive value of the metabolite model increased (AUC = 0.75). Longitudinal analyses showed an increase in the myoinositol/citrate ratio (p < 0.001) in fast progressors, while no significant change was found in those with slow progression, which is in-line with an overall increase in the myoinositol/citrate ratio as GFR declines.

conclusionA metabolic profile, measured at a single time point, showed at least equivalent prognostic performance to an imaging-based risk marker in ADPKD. Changes in urinary metabolites over a 3-year follow-up period were associated with a fast progressive disease course.

Indexed as

Polycystic Kidney, Autosomal DominantCitric AcidDisease ProgressionFemaleGlomerular Filtration RateHumansInositolKidneyMaleMiddle AgedCitric AcidInositolAutosomal dominant polycystic kidney diseaseBiomarkerEstimated glomerular filtration rate slopeProgressionUrine metabolites

Identifiers

PMID35613556
PMCPMC9393825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.